Risk of stroke among individuals on selective serotonin reuptake inhibitors (SSRIs) versus non-SSRI antidepressants: a population-based retrospective cohort study and meta-analysis.

J Affect DisordApr 22, 2026 (epub)
Clinical ResearchPsychiatry

Qi Sun, Paco Chun Yeung Wong, Jessie Ching Yan Su et al.

✦ AI-curated · Sources linked

In 30 seconds

This population-based retrospective cohort study and meta-analysis evaluated the stroke risk associated with selective serotonin reuptake inhibitors (SSRIs) compared to non-SSRI antidepressants among 124,854 patients in Hong Kong. The study found that SSRI users had an adjusted hazard ratio of 0.95 (95% CI 0.77-1.17) for stroke, indicating a non-significant lower risk.

Key findings

  • SSRI users had an adjusted HR of 0.95 for stroke compared to non-SSRI users.
  • The pooled relative risk from the meta-analysis was 0.94 (95% CI 0.83-1.06).
  • Findings were consistent across ischemic and hemorrhagic stroke subgroups.
  • The study included 124,854 individuals, with 56,279 being SSRI users.

Why it matters

Understanding the stroke risk associated with antidepressants is crucial for clinicians when prescribing these medications, especially in patients with pre-existing stroke risk factors. This study provides evidence that SSRIs may not increase stroke risk compared to non-SSRIs.

Source

PubMed · PMID 42031018

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.